Joseph Douglas Lyon, who serves as Chief Accounting & Technology Officer at Corcept Therapeutics Inc. (NASDAQ:CORT), executed a sale of company common stock on May 27, 2026. The transaction involved the disposal of 5,000 shares, purchased at a price point of $65.00 per share, resulting in total proceeds of $325,000.
Following this recent divestiture, Lyon's direct holdings in Corcept Therapeutics common stock amount to 6,230 shares. This current balance is composed of several restricted stock awards with varying grant dates and vesting schedules. Specifically, the total includes 749 shares from an award granted on June 2, 2025; 200 shares from a grant made on September 2, 2025; 178 shares derived from an award dated December 1, 2025; and 398 shares stemming from an award issued on March 2, 2026. These restricted stock awards are structured to vest completely on the one-year anniversary of their respective grant dates, contingent upon the Reporting Person meeting stipulated requirements.
In parallel corporate developments, Corcept Therapeutics recently released its first-quarter financial results for 2026. The company reported total revenues totaling approximately $165 million. This figure represented a shortfall when compared to the consensus estimate of $186 million that had been established by analysts.
Despite the Q1 revenue miss, Corcept provided an upward revision for its full-year revenue guidance. Management raised expectations for annual revenue to fall within a range of $950 million and $1.05 billion. This increased financial projection is attributed in part to the successful launch of Lifyorli.
The company also presented encouraging data during its participation at the ASCO 2026 Annual Meeting, drawing attention to its Phase 3 ROSELLA trial results. The study focused on ovarian cancer patients receiving treatment with Lifyorli combined with nab-paclitaxel. The reported outcome demonstrated a notable 35% reduction in the risk of death for this patient group. Furthermore, the median overall survival period achieved using this combination therapy was measured at 16.0 months, significantly exceeding the 11.9 months observed when only receiving nab-paclitaxel.
On the regulatory front, Corcept Therapeutics has announced plans to resubmit its New Drug Application (NDA) for relacorilant to the U.S. Food and Drug Administration (FDA). This resubmission follows a request from the FDA seeking additional analyses pertaining to the drug's development profile.
In addition to these operational updates, H.C. Wainwright maintained an investment rating on Corcept shares, elevating its price target. The firm raised its recommended price for CORT to $75, up from a previous target of $65, while maintaining a